Skip to content

Direct vision-endoscopic retrograde appendicitis therapy (D-ERAT) for treatment of acute uncomplicated appendicitis: A prospective multicenter randomized clinical trial

Direct vision-endoscopic retrograde appendicitis therapy (D-ERAT) for treatment of acute uncomplicated appendicitis: A prospective multicenter randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072691
Enrollment
Unknown
Registered
2023-06-21
Start date
2023-07-01
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute appendicitis

Interventions

Experimental group:direct vision-endoscopic retrograde appendicitis therapy
Control group:endoscopic retrograde appendicitis therapy

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or older; 2. Diagnosis of acute uncomplicated appendicitis by following presentations: (1) Clinical suspicion of acute uncomplicated appendicitis and Alvarado scores above 5; (2) CT scan determines acute uncomplicated appendicitis: Clear visualization of the appendix with a diameter above 6 mm (essential criterion); With or without: 1) peri-appendiceal fat stranding; 2) appendicolith(s); 3) the wall of periappendiceal bowel become thicker (cecum >4 mm, ileum >2 mm); Absence any of the following items of complicated appendicitis: 1) extraluminal air; 2) periappendiceal fluid; 3) disseminated intraperitoneal fluid. 3. Written informed consent obtained from patients or their legal representatives.

Exclusion criteria

Exclusion criteria: 1. Patients with acute uncomplicated appendicitis due to non-appendicolith(s) causes and complex appendicitis with appendiceal perforation, abdominal abscess, acute intestinal obstruction, and acute diffuse peritonitis found preoperatively or intraoperatively; 2. Patients with severe infectious or widespread diseases or concurrent acute abdominal conditions; 3. Patients with contraindications to colonoscopy or endoscopic procedures, e.g. with cardiopulmonary and other insufficiencies to tolerate endoscopy; at high risk of shock or gastrointestinal perforation; with impaired coagulation mechanisms and bleeding tendencies; with long-term steroids;. 4. Any terminal illness with life expectancy less than 6 months; 5. Pregnant women or lactating women; 6. Patients who have difficulty cooperating through comprehensive assessment, such as those who refuse to accept research measures or who have a history of mental illness 7. Patients with laxative and contrast media allergies; 8. Patients with a previous history of inflammatory bowel disease (IBD); 9. Patients who have taken part in other studies that can affect the results of the present study.

Design outcomes

Primary

MeasureTime frame
Appendicolith clearance rate;

Secondary

MeasureTime frame
Technical success rate;Recurrent appendicitis rate;The overall complication rate;Duration of post-treated pain;The decline time of inflammation index;Length of postoperative hospital stay;procedure time;X ray application time;body temperature normalized time;

Countries

China

Contacts

Public ContactXin Yang

The First Affiliated Hospital of Chongqing Medical University

305307293@qq.com+86 138 8377 5022

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026